\u7814\u7a76\u4e3b\u984c\uff1a\u4e73\u764c\u7279\u5b9a\u7a81\u8b8a\u5c0d\u4e9e\u6d32\u75c5\u4eba\u4e4b\u5f71\u97ff
\n\u64b0\u5beb\uff1a\u5b78\u751f\u66fe\u5b50\u6d0b<\/p>\n
\u4e73\u764c\u505a\u70ba\u76f8\u7576\u5e38\u898b\u7684\u60e1\u6027\u816b\u7624\u985e\u578b\uff0c\u4e26\u662f\u53f0\u7063\u751a\u81f3\u5168\u7403\u5973\u6027\u764c\u75c7\u76f8\u95dc\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u4e00\u76f4\u662f\u71b1\u9580\u7684\u751f\u91ab\u7814\u7a76\u4e3b\u984c\u3002\u4e0d\u8ad6\u5f9e\u8868\u5fb5\u5230\u75c5\u4eba\u7684\u57fa\u56e0\u578b\uff0c\u6291\u6216\u662f\u81f4\u75c5\u56e0\u5b50\u3001\u5404\u5f0f\u7642\u6cd5\u7684\u6548\u679c\u6bd4\u8f03\u8207\u6dfa\u5728\u7684\u76f8\u95dc\u7a81\u8b8a\u57fa\u56e0\uff0c\u5982\u719f\u77e5\u7684BRCA1\u8207BRCA2\u7b49\uff0c\u751f\u91ab\u754c\u5df2\u7d2f\u7a4d\u8a31\u591a\u7684\u7814\u7a76\u6210\u679c\uff0c\u4f46\u773e\u591a\u7684\u7814\u7a76\u8cc7\u6599\u7686\u662f\u53d6\u81ea\u65bc\u897f\u65b9\u7684\u75c5\u60a3\uff0c\u7d50\u679c\u662f\u5426\u6703\u56e0\u5730\u57df\u4e0d\u540c\u800c\u6709\u5dee\u7570\u4ecd\u5c6c\u672a\u77e5\uff0c\u6545\u9ec3\u6559\u6388\u7684\u7814\u7a76\u5718\u968a\u65bc\u53bb\u5e74\u767c\u8868\u4ed6\u5011\u5c0d\u65bc\u4e9e\u6d32\u4e73\u764c\u75c5\u60a3\u7684\u76f8\u95dc\u7814\u7a76\u6210\u679c\u3002<\/p>\n
\u4e73\u764c\u6709\u591a\u7a2e\u4e0d\u540c\u7684\u4e9e\u578b\uff0c\u5e38\u4ee5\u764c\u7d30\u80de\u8868\u9762\u4e0a\u662f\u5426\u5448\u73fe\u6307\u5b9a\u53d7\u9ad4\u505a\u70ba\u5206\u985e\u4f9d\u64da\uff0c\u5176\u4e2d\u5305\u542b\u52d5\u60c5\u6fc0\u7d20\u53d7\u9ad4\uff08Estrogen receptor, ER\uff09\u3001\u9ec3\u9ad4\u6fc0\u7d20\u53d7\u9ad4\uff08Progesterone receptor, PR\uff09\u8207\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4\uff08Human epidermal growth factor receptor-2, Her2\uff09\u4e09\u8005\u3002\u82e5\u764c\u7d30\u80de\u819c\u4e0a\u7686\u672a\u8868\u73fe\u4ee5\u4e0a\u4e09\u7a2e\u53d7\u9ad4\uff0c\u5247\u5c07\u8a72\u985e\u578b\u7684\u4e73\u764c\u7a31\u4e4b\u70ba\u4e09\u9670\u6027\u4e73\u764c\uff08Triple-negative breast cancer, TNBC\uff09\u3002\u4e09\u9670\u6027\u4e73\u764c\u56e0\u7f3a\u4e4f\u76f8\u95dc\u7684\u53d7\u9ad4\uff0c\u6545\u7121\u6cd5\u5229\u7528\u6a19\u9776\u578b\u8377\u723e\u8499\u6cbb\u7642\uff0c\u800c\u9020\u6210\u8f03\u5dee\u7684\u9810\u5f8c\u8207\u8f03\u4f4e\u7684\u75ca\u7652\u7387\uff0c\u4e5f\u6709\u8f03\u9ad8\u7684\u6a5f\u7387\u7522\u751f\u5fa9\u767c\u3002<\/p>\n
\u9ec3\u6559\u6388\u53ca\u5176\u7814\u7a76\u5718\u968a\u6536\u96c6\u4e86\u53f0\u7063128\u4f4d\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\u7684\u75c5\u4eba\u4ee5\u53ca4754\u4f4d\u672a\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\u75c5\u4eba\u7684\u91ab\u7642\u7d00\u9304\u5f8c\u767c\u73fe\uff0c\u5728\u4e9e\u6d32\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\u7684\u75c5\u60a3\u6703\u66f4\u65e9\u7f79\u60a3\u4e73\u764c\uff08BRCA vs. Non-BRCA: 43.9\u6b72 vs. 53.2\u6b72\uff09\uff0c\u540c\u6642\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\u7684\u75c5\u60a3\u9664\u6709\u986f\u8457\u9ad8\u7684\u6a5f\u7387\u7f79\u60a3\u4e09\u9670\u6027\u4e73\u764c\uff08BRCA vs. Non-BRCA: 52% vs. 12%, p < 0.001\uff09\uff0c\u4e5f\u6709\u8f03\u9ad8\u7684\u6a5f\u7387\u5f62\u6210\u5c0d\u5074\u4e73\u764c\u3002\u6b64\u5916\u4ed6\u5011\u767c\u73fe\u4e0d\u50c5\u662f\u5728\u6b50\u7f8e\u7684\u4e73\u764c\u75c5\u60a3\uff0c\u4e9e\u6d32\u7684\u75c5\u60a3\u82e5\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\uff0c\u5247\u4e5f\u6709\u9ad8\u6a5f\u7387\u6703\u7f79\u60a3\u4e73\u764c\u4ee5\u53ca\u7522\u751f\u5c0d\u5074\u4e73\u764c\u3002\u900f\u904e\u9019\u9805\u7814\u7a76\uff0c\u9ec3\u6559\u6388\u767c\u73fe\u5728\u4e9e\u6d32\u7684\u75c5\u60a3\u82e5\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\u800c\u6703\u6709\u8f03\u9ad8\u7684\u6a5f\u7387\u7f79\u60a3\u4e09\u9670\u6027\u4e73\u764c\u540c\u6642\u6709\u986f\u8457\u4e0a\u5347\u7684\u6a5f\u7387\u767c\u751f\u5c0d\u5074\u4e73\u764c\uff0c\u540c\u6642\u900f\u904e\u5206\u6790\u8cc7\u6599\u986f\u793a\uff0c\u82e5\u5e36\u6709BRCA1\u57fa\u56e0\u7a81\u8b8a\u4e26\u7f79\u60a3\u4e09\u9670\u6027\u4e73\u764c\u7684\u75c5\u60a3\uff0c\u5c0d\u6bd4\u975e\u5e36\u6709BRCA\u57fa\u56e0\u7a81\u8b8a\u7684\u4e73\u764c\u75c5\u60a3\uff0c\u5c07\u6709\u4e94\u500d\u4e0a\u5347\u7684\u6a5f\u7387\u767c\u751f\u5c0d\u5074\u4e73\u764c\uff0c\u6545\u9ec3\u6559\u6388\u53ca\u5176\u7814\u7a76\u5718\u968a\u65bc\u6587\u672b\u5c31\u63d0\u53ca\uff0c\u5728\u4e9e\u6d32\u7684BRCA\u57fa\u56e0\u7a81\u8b8a\u7684\u907a\u50b3\u8aee\u8a62\u4ee5\u53ca\u8ffd\u8e64\u4ecd\u9808\u8981\u6301\u7e8c\u6539\u9032\uff0c\u4ee5\u65e9\u671f\u767c\u73fe\u4e26\u589e\u52a0\u75c5\u4eba\u7684\u5b58\u6d3b\u7387 [1]\u3002<\/p>\n
\u9664\u63a2\u7a76\u4e0d\u540c\u5730\u5340\u7684\u4e73\u764c\u75c5\u60a3\u662f\u5426\u5b58\u5728\u5dee\u7570\uff0c\u9ec3\u6559\u6388\u4e5f\u947d\u7814\u65bc\u4e73\u764c\u7684\u5176\u4ed6\u76f8\u95dc\u7814\u7a76\uff0c\u5982\u5229\u7528\u5faa\u74b0\u816b\u7624\uff08Circulating tumor\uff09DNA\u4f5c\u70ba\u4e73\u764c\u60a3\u8005\u5fa9\u767c\u7684\u9810\u6e2c\u6307\u6a19\u7269 [2]\uff0c\u6291\u6216\u662f\u6559\u6388\u4e5f\u8207\u6240\u4e0a\u7684\u5f35\u745e\u5cf0\u6559\u6388\u5408\u4f5c\u4f7f\u7528\u5377\u7a4d\u795e\u7d93\u7db2\u7d61\uff08Convolutional neural network, CNN\uff09\u4f86\u5b78\u7fd2\u4e73\u764c\u8d85\u97f3\u6ce2\u5716\u50cf\u9032\u884c\u8f14\u52a9\u8a3a\u65b7 [3]\uff0c\u7d9c\u5408\u4ee5\u4e0a\u9ec3\u6559\u6388\u805a\u7126\u65bc\u4e73\u764c\u65b9\u9762\u7684\u7814\u7a76\uff0c\u4e26\u900f\u904e\u751f\u7269\u8cc7\u8a0a\u5206\u6790\u6578\u64da\u7684\u65b9\u5f0f\u4f86\u7814\u7a76\u76f8\u95dc\u554f\u984c\u3002<\/p>\n
<\/p>\n
Research Topic: The effect of BRCA on Asian breast cancer patients<\/p>\n
Breast cancer, a common type of malignant tumor and the leading cause of cancer-related deaths among women in Taiwan and even globally, has long been a popular topic of biomedical research. The biomedical field has accumulated a lot of research results including patients\u2019 phenotype and genotype, as well as the risk factors, the effectiveness of various therapies and the underlying genetic mutations such as the well-known BRCA1 and BRCA2. However, most of the research data are collected from Western patients, and it remains unknown whether there are differences due to regional difference. Therefore, Prof. Huang’s research team published their results on Asian breast cancer patients last year.<\/p>\n
Breast cancer has various subtypes, which are commonly classified based on whether specific receptors are expressed on the cancer cell surface. These include the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her2). The subtype of breast cancer is called triple-negative breast cancer (TNBC) when none of these receptors are expressed on the cancer cell membrane. Due to the lack of relevant receptors in TNBC, patients cannot be treated with targeted hormone therapy, resulting in worse prognosis, lower cure rates, and a higher risk of recurrence or develop contralateral breast (CBC).<\/p>\n
Prof. Huang and his research team collected medical records of 128 patients with BRCA mutation and 4754 patients without carrying BRCA mutation in Taiwan. They found that Asian patients with BRCA mutation are more likely to develop breast cancer at an earlier age (BRCA vs. Non-BRCA: 43.9 years vs. 53.2 years) and have a significantly higher probability of developing TNBC (BRCA vs. Non-BRCA: 52% vs. 12%, p < 0.001). Through this study, Prof. Huang found that Asian patients with BRCA mutations have a higher probability of developing breast cancer and CBC, which is same as the result we known on European and American patients. Furthermore, through analyzing data, they showed that patients with BRCA1 mutations and TNBC have a five-fold probability of developing CBC, compared to breast cancer patients without BRCA mutation. Therefore, Prof. Huang and his research team mentioned in the conclusion that genetic counseling and follow-up of BRCA mutations in Asia still need to be improved in order to detect and increase the survival rate of patients at an early stage [1].<\/p>\n
In addition to studying whether there are differences in breast cancer patients in different regions, Prof. Huang also conducts research on other related topics, such as using circulating tumor DNA as a predictive marker for breast cancer recurrence [2], or collaborating with Prof. Zhang to train a convolutional neural network (CNN) model on breast cancer ultrasound images for assistive diagnosis [3]. Generally, Prof. Huang mainly focuses on breast cancer related field and uses bioinformatics data analysis to study related questions.<\/p>\n
<\/p>\n[1] Lin, P. H., Chen, S. C., Tseng, L. M. et al.<\/em> (2022). Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Res. Treat.<\/em> 192<\/strong>, 629-637. https:\/\/doi.org\/10.1007\/s10549-021-06446-7<\/a><\/p>\n[2] Lin, P. H., Wang, M. Y., Lo, C. et al.<\/em> (2021). Circulating Tumor DNA as a Predictive Marker of Recurrence for Patients With Stage II-III Breast Cancer Treated With Neoadjuvant Therapy. Front. Oncol<\/em>. 11<\/strong>, 736769. https:\/\/doi.org\/10.3389\/fonc.2021.736769<\/a><\/p>\n[3] Moon, W. K., Huang, Y. S., Hsu, C. H. et al.<\/em> (2020). Computer-aided tumor detection in automated breast ultrasound using a 3-D convolutional neural network. Comput. Methods Programs Biomed. <\/em>190<\/strong>, 105360. https:\/\/doi.org\/10.1016\/j.cmpb.2020.105360<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" \u7814\u7a76\u4e3b\u984c\uff1a\u4e73\u764c\u7279\u5b9a\u7a81\u8b8a\u5c0d\u4e9e\u6d32\u75c5\u4eba\u4e4b\u5f71\u97ff \u64b0\u5beb\uff1a\u5b78\u751f\u66fe\u5b50\u6d0b \u4e73\u764c\u505a\u70ba\u76f8\u7576\u5e38\u898b\u7684\u60e1\u6027\u816b\u7624\u985e\u578b\uff0c\u4e26\u662f\u53f0\u7063\u751a\u81f3\u5168\u7403\u5973\u6027 […]\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[19],"tags":[],"class_list":["post-2338","post","type-post","status-publish","format-standard","hentry","category-award"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts\/2338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2338"}],"version-history":[{"count":1,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts\/2338\/revisions"}],"predecessor-version":[{"id":2339,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=\/wp\/v2\/posts\/2338\/revisions\/2339"}],"wp:attachment":[{"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bebi.ntu.edu.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}